Eylea (aflibercept) 8 mg with extended 6-month treatment interval recommended for approval in EU – Bayer
Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has issued a positive opinion recommending a label extension for Eylea 8 mg… read more.